CLINICAL_TRIALS
trial_result
· 2014-06-11
Clinical Trial Update: ToleroMune House Dust Mite (HDM) Tolerability Study [Phase 2]
Summary
Phase 2 tolerability trial of ToleroMune for rhinoconjunctivitis (HDM) has completed; this update highlights tolerability findings from the study.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Circassia Limited | Conditions: Rhinoconjunctivitis | Phase 2 | Status: COMPLETED